Aromatase inhibitors, tamoxifen, and endometrial cancer in breast cancer survivors
- PMID: 25757699
- PMCID: PMC4565775
- DOI: 10.1002/cncr.29332
Aromatase inhibitors, tamoxifen, and endometrial cancer in breast cancer survivors
Abstract
Background: The risks of both endometrial cancer and postmenopausal breast cancer are increased by obesity and higher endogenous estrogen levels. Although aromatase inhibitors reduce breast cancer incidence, their influence on endometrial cancer is uncertain.
Methods: The authors investigated this issue in a cohort of 17,064 women who were diagnosed with hormone receptor-positive breast cancer in an integrated group practice health plan. Information on demographics, comorbidities, and the receipt of adjuvant endocrine therapy was available from electronic medical records and pharmacy records, respectively. Endometrial cancer information was obtained from the health plan's Surveillance, Epidemiology, and End Results-affiliated tumor registry, and rates were compared across endocrine therapy groups (aromatase inhibitor, n = 5303; tamoxifen, n = 5155; switchers: both [n = 3787] or none [n = 2819]) using multivariable adjusted Cox proportional-hazards models.
Results: Endometrial cancer incidence was a statistically significant 48% lower in the aromatase inhibitor group versus the tamoxifen group (hazard ratio, 0.52; 95% confidence interval, 0.31-0.87; P = .01). Endometrial cancer incidence was 29% lower in the aromatase inhibitor group versus the no endocrine therapy group (hazard ratio, 0.71; 95% confidence interval, 0.37-1.35; P = .30) and 33% lower in the aromatase inhibitor group versus the tamoxifen group (hazard ratio, 0.67; 95% confidence interval, 0.42-1.06; P = .08), but neither difference was statistically significant. Associations were stronger among those with good drug adherence.
Conclusions: In a community-based, integrated health plan setting, endometrial cancer incidence was lower in women who were receiving an aromatase inhibitor compared with those who were receiving tamoxifen. In addition, aromatase inhibitors may mitigate the incidence of tamoxifen-associated endometrial cancer. Although there were somewhat fewer endometrial cancers in the aromatase inhibitor group versus the no endocrine therapy group, further studies are needed for the definitive assessment of this potential association.
Keywords: aromatase inhibitors; breast cancer; chemoprevention; endometrial cancer; tamoxifen.
© 2015 American Cancer Society.
Conflict of interest statement
Similar articles
-
Utilization of gynecologic services in women with breast cancer receiving hormonal therapy.Am J Obstet Gynecol. 2017 Jul;217(1):59.e1-59.e12. doi: 10.1016/j.ajog.2017.03.011. Epub 2017 Mar 21. Am J Obstet Gynecol. 2017. PMID: 28341383 Free PMC article.
-
Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis.J Natl Cancer Inst. 2011 Sep 7;103(17):1299-309. doi: 10.1093/jnci/djr242. Epub 2011 Jul 9. J Natl Cancer Inst. 2011. PMID: 21743022 Review.
-
Adjuvant endocrine therapy of perimenopausal and recently postmenopausal women with hormone receptor-positive breast cancer.Clin Breast Cancer. 2014 Jun;14(3):147-53. doi: 10.1016/j.clbc.2013.12.010. Epub 2013 Dec 27. Clin Breast Cancer. 2014. PMID: 24503025 Review.
-
Long-term "protective" effect of aromatase inhibitors on the endometrium of postmenopausal breast cancer patients.Breast Cancer Res Treat. 2009 Jan;113(2):321-6. doi: 10.1007/s10549-008-9941-4. Epub 2008 Feb 23. Breast Cancer Res Treat. 2009. PMID: 18297393
-
A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.N Engl J Med. 2005 Dec 29;353(26):2747-57. doi: 10.1056/NEJMoa052258. N Engl J Med. 2005. PMID: 16382061 Clinical Trial.
Cited by
-
Utilization of gynecologic services in women with breast cancer receiving hormonal therapy.Am J Obstet Gynecol. 2017 Jul;217(1):59.e1-59.e12. doi: 10.1016/j.ajog.2017.03.011. Epub 2017 Mar 21. Am J Obstet Gynecol. 2017. PMID: 28341383 Free PMC article.
-
Effect of metformin use on the risk and prognosis of endometrial cancer: a systematic review and meta-analysis.BMC Cancer. 2018 Apr 18;18(1):438. doi: 10.1186/s12885-018-4334-5. BMC Cancer. 2018. PMID: 29669520 Free PMC article. Review.
-
Using human experience to identify drug repurposing opportunities: theory and practice.Br J Clin Pharmacol. 2019 Apr;85(4):680-689. doi: 10.1111/bcp.13851. Epub 2019 Feb 3. Br J Clin Pharmacol. 2019. PMID: 30648285 Free PMC article. Review.
-
Landscape of Endometrial Cancer: Molecular Mechanisms, Biomarkers, and Target Therapy.Cancers (Basel). 2024 May 27;16(11):2027. doi: 10.3390/cancers16112027. Cancers (Basel). 2024. PMID: 38893147 Free PMC article. Review.
-
Disease trajectories and mortality among women diagnosed with breast cancer.Breast Cancer Res. 2019 Aug 16;21(1):95. doi: 10.1186/s13058-019-1181-5. Breast Cancer Res. 2019. PMID: 31420051 Free PMC article.
References
-
- Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics 2014. CA Cancer J Clin. 2014;64:9–29. - PubMed
-
- Chlebowski RT, Aiello E, McTiernan A. Weight loss in breast cancer patient management. J. Clin Oncol. 2002;20:1128–1143. - PubMed
-
- Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625–1638. - PubMed
-
- Protani M, Coory M, Martin JH. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat. 2010;123:627–635. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical